RRMS Patients May Look To Alternatives To Lemtrada
The enhanced restrictions being placed on anti-RRMS drug Lemtrada are concerning to patients that have run out of options
Wednesday, November 6, 2019 - Patients suffering from the advanced stages of relapse-remitting multiple sclerosis (RRMS) should look to anti-seizure drug Mavenclad before resorting to Lemtrada given the extreme adverse side effects Lemtrada carries. The U.S. Food and Drug Administration (FDA) has recently approved Mavenclad (cladribine) to treat relapsing forms of multiple sclerosis (MS) in adults when other therapies have proved inadequate. According to the FDA, Billy Dunn, M.D., director of the Division of Neurology Products in the FDA Center for Drug Evaluation and Research told the agency: "The approval of Mavenclad represents an additional option for patients who have tried another treatment without success." Mavenclad demonstrated its effectiveness by decreasing the number of relapses in RRMS patients as well as slowing the progression of the disease in a clinical trial of 1300 RRMS patients. Patients in the study had at least one RRMS remission within the previous 12 months. While safer than Lemtrada, Mavenclad carries a boxed warning and should not be used by women who are pregnant. Women should avoid Mavenclad if they will be sexually and not using birth control within 6 months from the date of staring the drug.
In spite of being the most effective drug on the market to fight RRMS, Lemtrada's side effects are so severe that Europe's Medicine's Agency (EMA) placed additional restrictions on the availability of the drug limiting it to only highly active RRMS patients. According to the EMA's drug safety committee, "Lemtrada (alemtuzumab) should be given only to people with highly active relapsing-remitting multiple sclerosis (RRMS)." Lemtrada is now allowed only when no other drug has worked and if the patient's multiple sclerosis is rapidly worsening. The prospective patient is also required to have had at least two relapses in the previous 12 months and suffered brain damage. Lemtrada stroke attorneys represent American families and offer a free consultation with no obligation to file a lawsuit claim.
Lemtrada's restrictions are due to the severe, life-threatening side effects, including the likelihood of experiencing a paralyzing stroke, that Lemtrada patients have suffered and have been reported to the FDA. According to DrugWatch.com, "In November 2018, the FDA released a safety communication warning about a rare but serious risk of stroke and tears in the lining of the arteries in the head and neck with Lemtrada. These tears are called arterial dissections. These conditions can lead to permanent disability or death. Most of the people who suffered these complications developed symptoms within one day of receiving the drug. One patient had symptoms three days after treatment." 12 of the 13 reported cases of arterial dissection occurred within 24 hours of receiving a Lemtrada infusion. Lemtrada is administered to patients in two, five-day treatments, one year apart for two consecutive years. In extreme cases, the third treatment in year three is permitted. Lemtrada patients also have a 50-50 chance of developing serious, life-threatening autoimmune disorders, Including "kidney, liver and thyroid problems, and immune thrombocytopenic purpura, a condition in which the body attacks platelets," according to DrugWatch. Lemtrada patients should be screened for pre-existing conditions before beginning treatments and monitored closely for at least three days afterward.
In response to the need for an alternative treatment of last resort for RLMS patients, the FDA approved "Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease." Like Lemtrada and Tecfidera, Mavenclad is recommended as a drug of last resort when other RLMS drugs have failed. Mavenclad has performed well in clinical trials consisting of over 1300 RLMS patients that have had at least one relapse episode within the last 12 months. According to the FDA, "Mavenclad significantly decreased the number of relapses experienced by these patients compared to placebo. Mavenclad also reduced the progression of disability compared to placebo." Mavenclad carries an FDA boxed warning due to the drug's potential to cause fetal harm. Women who are pregnant or will be sexually active and do not use birth control within 6 months from the date of staring Mavenclad should not use the drug.
More Recent Lemtrada Stroke Lawsuit News:
- Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
- The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
- RRMS Has Different Stages With Different Symptoms | 4/5/2021
- Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
- Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
- Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
- MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
- Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
- Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
- Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
- People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
- Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
- Lemtrada Patients Have May Have Safer Options | 12/8/2020
- Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
- Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
- Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
- Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
- Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
- Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
- Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
- Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
- Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
- Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
- Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
- RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
- New Information About COVID19 and Taking Lemtrada | 7/16/2020
- The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
- Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
- A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
- Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
- Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
- RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
- Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
- Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
- Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
- Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
- Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
- Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
- Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
- Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
- Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
- Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
- Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
- Lemtrada Fears May Be Overdone | 1/30/2020
- Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
- One Last Lemtrada Warning for 2019 | 1/2/2020
- RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
- Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
- Lemtrada Side Effect Awareness Requirements | 12/11/2019
- Lemtrada is serious medication for a serious condition | 11/21/2019
- More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
- Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
- Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
- Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
- Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
- RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
- Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
- Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
- Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
- Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
- Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
- Lemtrada Patients Report Promising Results | 8/1/2019
- The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
- What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
- Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
- Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
- Treating Multiple Sclerosis From Many Angles | 6/21/2019
- Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
- A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
- A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
- Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
- The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
- Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
- The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
- The Pros and Cons of Lemtrada Therapy | 4/19/2019
- Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
- Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
- MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
- Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
- Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
- Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019
No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.